SEC Company Response from Sorrento Therapeutics, Inc. (SRNE) (CIK 0000850261) — Mar 18, 2020
Sorrento Therapeutics, Inc. (SRNE) (CIK 0000850261)
Date: March 18, 2020 · CIK: 0000850261 · Accession: 0001104659-20-035274
AI Filing Summary & Sentiment
File numbers found in text: 333-237142
Letter
Sorrento Therapeutics, Inc.
4955 Directors Place
San Diego, California 92121
March 18, 2020
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549-0406
Re: Sorrento Therapeutics, Inc.
Registration Statement on Form S-3, Filed March 13, 2020
File No. 333-237142
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Sorrento Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the Registration Statement on Form S-3 (Registration No. 333-237142) of the Company (the “Registration Statement”), filed with the Securities and Exchange Commission on March 13, 2020 be accelerated so that such Registration Statement shall become effective at 4:30 p.m. (Eastern Time) on March 20, 2020, or as soon as possible thereafter. As of the date above, there is no managing or principal underwriter for any of the Company’s securities that may be offered pursuant to the Registration Statement. Future managing or principal underwriters, if any, will be identified in a prospectus supplement to the Registration Statement at the time of the offering.
The Company hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Company hereby authorizes Mr. Hartlin to orally modify or withdraw this request for acceleration.
Sincerely,
SORRENTO THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Sorrento Therapeutics, Inc.
4955 Directors Place
San Diego, California 92121
March 18, 2020
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549-0406
Re: Sorrento Therapeutics, Inc.
Registration Statement on Form S-3,
Filed March 13, 2020
File No. 333-237142
Ladies and Gentlemen:
Pursuant to Rule 461
under the Securities Act of 1933, as amended, Sorrento Therapeutics, Inc. (the “Company”) hereby requests
that the effectiveness of the Registration Statement on Form S-3 (Registration No. 333-237142) of the Company (the “Registration
Statement”), filed with the Securities and Exchange Commission on March 13, 2020 be accelerated so that such Registration
Statement shall become effective at 4:30 p.m. (Eastern Time) on March 20, 2020, or as soon as possible thereafter. As of the date
above, there is no managing or principal underwriter for any of the Company’s securities that may be offered pursuant to
the Registration Statement. Future managing or principal underwriters, if any, will be identified in a prospectus supplement to
the Registration Statement at the time of the offering.
The Company hereby
confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act
of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement.
It would be appreciated
if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin
of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Company hereby authorizes
Mr. Hartlin to orally modify or withdraw this request for acceleration.
Sincerely,
SORRENTO THERAPEUTICS, INC.
By:
/s/ Henry Ji, Ph.D.
Henry Ji, Ph.D.
President and Chief Executive Officer
cc: Jeffrey
T. Hartlin, Paul Hastings LLP